Sales, profits jump at Smith & Nephew

(Sharecast News) - Smith & Nephew posted a jump in annual revenues and profits on Monday, as new products helped bolster demand at the medical devices specialist. Revenues in the year to 31 December rose 6.3%, or by 5.3% on an organic basis, to $6.16bn. Trading profit spiked 15.5% at $1.21bn.

Smith & Nephew said growth had been supported by robust demand across all divisions, as well the launch of new products, favourable currency effects and a strong end to the year.

In particular, orthopaedics saw its best quarter in more than two years, the blue chip noted of its biggest division, with underlying sales up 7.9% at $667m. Revenues were also stronger in sports medicine and ENT, and in advanced wound management, up 7.3% and 2.8% respectively.

Looking to the current year, Smith & Nephew reiterated guidance for underlying annual revenue growth of around 6% and organic trading profit growth of around 8%.

The acquisition of Integrity Orthopaedics, however, was expected to be "marginally dilutive" to trading profit during the year. Including the dilution, trading profit was slated to come in around $1.3bn in 2026.

Deepak Nath, chief executive, said: "During the year, newer products drove strong, broad-based performance and underlying revenue growth above 5% for all three business units, and we look forward to a strong cadence of further new product introductions in 2026.

"Our Rise strategy, launched in December...is our roadmap to reach more patients, unlock new categories of innovation, scale through strategic investment and executive efficiently.

"2026 is the first step in that journey and we are confidence in delivering an acceleration in growth and returns."